MIST Share Price Performance
US$1.36
-0.54 (-28.42%)
79.4% undervalued intrinsic discount
US$6.60
Fair Value
Price US$1.36
AnalystConsensusTarget US$6.60
Fair ValueUS$6.60
Share Pricen/a
Milestone Pharmaceuticals Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 26 Fair Values set on narratives written by author
MIST Community Narratives
AN
Fair Value US$6.6 79.4% undervalued intrinsic discount
Acute Cardiovascular Self Administration Will Reshape Treatment Patterns And Support Long Term Thesis
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Acute Cardiovascular Self Administration Will Reshape Treatment Patterns And Support Long Term Thesis
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for acute cardiovascular conditions, including paroxysmal supraventricular tachycardia through its intranasal etripamil product, CARDAMYST. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$6.6
79.4% undervalued intrinsic discount
Fair Value
Profit Margin
20.06%
Future PE
34.82x
Price in 2029
US$8.04
Trending Discussion
Recently Updated Narratives
AN
Acute Cardiovascular Self Administration Will Reshape Treatment Patterns And Support Long Term Thesis
Fair Value: US$6.6 79.4% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Milestone Pharmaceuticals Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.62
- 100.00%
- -4,078.78%
- 136.9%
About MIST
- Founded
- 2003
- Employees
- 33
- CEO
- WebsiteView website
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
